Gilead Sciences Inc. (GILD) Stock Analysis 2026

Gilead Sciences is a biopharmaceutical company that revolutionized HIV treatment and hepatitis C cure rates. The company's HIV franchise (Biktarvy, Descovy, and prevention drug Sunlenca) generates the majority of revenue and cash flow. Gilead cured Hepatitis C with its Sovaldi and Harvoni drugs in 2014-2015, generating extraordinary revenues before competition eroded the market. The company has invested heavily in oncology through acquisitions (Kite Pharma for CAR-T cell therapy, Immunomedics for breast cancer antibody-drug conjugates).

This chart shows how Gilead Sciences's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Gilead Sciences Inc. trades at a trailing P/E of 17.74x, generates $9.77B in free cash flow, runs a debt/equity ratio of 223.47, and converts shareholder equity into profit at a -20.7% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

26 analysts covering Gilead Sciences Inc. currently lean toward a Buy rating, with a mean 12-month price target of $157.41 (+4.9% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 1 valuation model to estimate GILD's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

GILD is currently in a golden cross pattern, trading above its 50-day average of $134.55 and above its 200-day average of $133.84. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

GILD's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.